Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon

J Dermatol. 2011 May;38(5):479-81. doi: 10.1111/j.1346-8138.2010.01088.x. Epub 2011 Jan 28.

Abstract

Pegylated or non-pegylated α-interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment with this drug. However, drug eruption or morbilliform eruptions due to interferons have been rarely reported so far. We herein describe a patient who developed morbilliform drug eruption under treatment with pegylated interferon. She was able to continue treatment after switching from pegylated interferon to conventional interferon.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Back
  • Drug Eruptions / etiology*
  • Drug Eruptions / pathology
  • Drug Substitution*
  • Female
  • Hepatitis B / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / adverse effects
  • Interferon-alpha / therapeutic use*
  • Polyethylene Glycols / adverse effects*
  • Recombinant Proteins
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • peginterferon alfa-2a